Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in...

Area of Science:

• Muscle biology
• Immunology
• Genetics

Background:

• Dysferlin is crucial for muscle function, yet its deficiency selectively impacts skeletal muscle over cardiac muscle.
• The precise molecular mechanisms underlying this selective vulnerability in dysferlinopathies remain incompletely understood.

Purpose of the Study:

• To investigate the molecular differences between cardiac and skeletal muscle in dysferlin deficiency.
• To identify novel pathways involved in skeletal muscle fiber injury in dysferlin-deficient muscular dystrophy.

Main Methods:

• Comparative analysis of intraindividual mRNA expression profiles in cardiac and skeletal muscles of dysferlin-deficient mice.
• Validation of gene and protein expression using multiple mouse models and patient samples.
• In vitro studies using human myotubes to assess complement susceptibility in the absence of CD55.
• Investigation of the regulatory role of the myostatin-SMAD pathway on decay-accelerating factor/CD55.

Main Results:

• Down-regulation of the complement inhibitor decay-accelerating factor/CD55 was observed exclusively in the skeletal muscle of dysferlin-deficient mice.
• This down-regulation was confirmed at both mRNA and protein levels across different mouse strains and in patients with dysferlin-deficient muscular dystrophy.
• Absence of CD55 significantly increased the susceptibility of human myotubes to complement-mediated damage.
• Evidence suggests that decay-accelerating factor/CD55 expression is regulated by the myostatin-SMAD pathway.

Conclusions:

• Dysferlin deficiency leads to skeletal muscle injury through a novel mechanism involving the down-regulation of decay-accelerating factor/CD55 and subsequent complement attack.
• This discovery highlights a potential therapeutic target for treating skeletal muscle weakness in dysferlin-deficient muscular dystrophy.